BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 30567203)

  • 1. Acute promyelocytic leukaemia presenting as necrotising fasciitis of the perineum (Fournier gangrene).
    Furtado VF; Batalini F; Staziaki PV; Prilutskiy A; Sloan JM
    BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30567203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [All-trans retinoic acid/arsenic trioxide combination therapy for a patient with acute promyelocytic leukemia on dialysis].
    Nagao R; Hosoba R; Yahagi Y; Gunji T; Uryu H; Hattori D; Momoki M; Yamazaki H
    Rinsho Ketsueki; 2019; 60(10):1431-1435. PubMed ID: 31695003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
    Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
    Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular remission without blood product support using all-trans retinoic acid (ATRA) induction and combined arsenic trioxide/ATRA consolidation in a Jehovah's Witness with de novo acute promyelocytic leukaemia.
    Kennedy GA; Marlton P; Cobcroft R; Gill D
    Br J Haematol; 2000 Dec; 111(4):1103-5. PubMed ID: 11167746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
    Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
    Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial.
    Zhang L; Zou Y; Chen Y; Guo Y; Yang W; Chen X; Wang S; Liu X; Ruan M; Zhang J; Liu T; Liu F; Qi B; An W; Ren Y; Chang L; Zhu X
    BMC Cancer; 2018 Apr; 18(1):374. PubMed ID: 29615003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone Marrow Findings in Patients With Acute Promyelocytic Leukemia Treated With Arsenic Trioxide.
    Miller KP; Venkataraman G; Gocke CD; Batista DA; Borowitz MJ; Burns KH; Pratz K; Duffield AS
    Am J Clin Pathol; 2019 Oct; 152(5):675-685. PubMed ID: 31305869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The economic research of arsenic trioxide for the treatment of newly diagnosed acute promyelocytic leukemia in China.
    Chen X; Hong Y; Zheng P; You X; Feng J; Huang Z; Wang Y
    Cancer; 2020 Jan; 126(2):311-321. PubMed ID: 31714584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
    Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
    Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis of Acute Promyelocytic Leukemia After Presentation to Neuro-Ophthalmology.
    Paxton AB; Micieli JA
    J Neuroophthalmol; 2022 Mar; 42(1):e181-e186. PubMed ID: 34483332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
    Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
    Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
    Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
    Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
    Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J
    Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous herald: leukaemia cutis as presenting manifestation of relapse in acute promyelocytic leukaemia.
    Balasubramanian P; Nampoothiri RV; Goni D; Malhotra P
    BMJ Case Rep; 2018 May; 2018():. PubMed ID: 29724869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards Optimizing Risk-adapted Treatment of APML in ATRA/ATO Era: How Can Prediction of Early Mortality Help?
    Buhtoiarov IN
    J Pediatr Hematol Oncol; 2021 May; 43(4):158. PubMed ID: 33625082
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
    Iland HJ; Collins M; Bradstock K; Supple SG; Catalano A; Hertzberg M; Browett P; Grigg A; Firkin F; Campbell LJ; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF;
    Lancet Haematol; 2015 Sep; 2(9):e357-66. PubMed ID: 26685769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Acute promyelocytic leukemia accompanied by scrotal Fournier's gangrene during ATRA treatment and relapsed as external ear tumor].
    Goto H; Tsurumi H; Kasahara S; Hara T; Yamada T; Sawada M; Tanabashi S; Kametani M; Moriwaki H
    Rinsho Ketsueki; 1998 Dec; 39(12):1169-74. PubMed ID: 10028849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Acute Promyelocytic Leukemia: New treatment strategies with ATRA and ATO - AML-BFM-Recommendations].
    Creutzig U; Dworzak M; von Neuhoff N; Rasche M; Reinhardt D
    Klin Padiatr; 2018 Oct; 230(6):299-304. PubMed ID: 30399642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.
    Sanford D; Lo-Coco F; Sanz MA; Di Bona E; Coutre S; Altman JK; Wetzler M; Allen SL; Ravandi F; Kantarjian H; Cortes JE
    Br J Haematol; 2015 Nov; 171(4):471-7. PubMed ID: 26205361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PHA-Induced Peripheral Blood Cytogenetics and Molecular Analysis: a Valid Diagnostic and Follow-up Modality for Acute Promyelocytic Leukemia Patients Treated with ATRA and/or Arsenic Tri-oxide.
    Baba SM; Azad NA; Shah ZA; Afroze D; Pandith AA; Jan A; Aziz SA; Dar FA
    Asian Pac J Cancer Prev; 2016; 17(4):1999-2006. PubMed ID: 27221887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.